MX2018013085A - Analisis mutacional de adn de plasma para la deteccion de cancer. - Google Patents

Analisis mutacional de adn de plasma para la deteccion de cancer.

Info

Publication number
MX2018013085A
MX2018013085A MX2018013085A MX2018013085A MX2018013085A MX 2018013085 A MX2018013085 A MX 2018013085A MX 2018013085 A MX2018013085 A MX 2018013085A MX 2018013085 A MX2018013085 A MX 2018013085A MX 2018013085 A MX2018013085 A MX 2018013085A
Authority
MX
Mexico
Prior art keywords
door
cancer
level
variant
parameter
Prior art date
Application number
MX2018013085A
Other languages
English (en)
Inventor
Peiyong Jiang
Kwan Chee Chan
Yuk-Ming Dennis Lo
Wai Kwun Rossa Chiu
Original Assignee
Univ Hong Kong Chinese
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Hong Kong Chinese filed Critical Univ Hong Kong Chinese
Publication of MX2018013085A publication Critical patent/MX2018013085A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J19/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J19/0046—Sequential or parallel reactions, e.g. for the synthesis of polypeptides or polynucleotides; Apparatus and devices for combinatorial chemistry or for making molecular arrays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1065—Preparation or screening of tagged libraries, e.g. tagged microorganisms by STM-mutagenesis, tagged polynucleotides, gene tags
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6853—Nucleic acid amplification reactions using modified primers or templates
    • C12Q1/6855—Ligating adaptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G16B30/10—Sequence alignment; Homology search
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
    • C12Q2525/10—Modifications characterised by
    • C12Q2525/191—Modifications characterised by incorporating an adaptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2535/00—Reactions characterised by the assay type for determining the identity of a nucleotide base or a sequence of oligonucleotides
    • C12Q2535/122—Massive parallel sequencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2537/00—Reactions characterised by the reaction format or use of a specific feature
    • C12Q2537/10—Reactions characterised by the reaction format or use of a specific feature the purpose or use of
    • C12Q2537/16—Assays for determining copy number or wherein the copy number is of special importance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2537/00—Reactions characterised by the reaction format or use of a specific feature
    • C12Q2537/10—Reactions characterised by the reaction format or use of a specific feature the purpose or use of
    • C12Q2537/165—Mathematical modelling, e.g. logarithm, ratio
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2539/00—Reactions characterised by analysis of gene expression or genome comparison
    • C12Q2539/10—The purpose being sequence identification by analysis of gene expression or genome comparison characterised by
    • C12Q2539/107—Representational Difference Analysis [RDA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/166—Oligonucleotides used as internal standards, controls or normalisation probes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Abstract

La presente invención se refiere a una frecuencia de mutaciones somáticas en una muestra biológica (por ejemplo, plasma o suero) de un sujeto sometido a la detección o monitoreo de cáncer, que se puede comparar con la del ADN constitucional del mismo sujeto. Un parámetro puede derivarse de estas frecuencias y utilizar para determinar una clasificación de un nivel de cáncer. Los falsos positivos pueden ser filtrados requiriendo que algún locus variante tenga al menos un número especificado de lecturas de secuencia variante (marcas), proporcionando así un parámetro más preciso. Las frecuencias relativas para los diferentes loci variantes pueden ser analizadas para determinar un nivel de heterogeneidad de los tumores en un paciente.
MX2018013085A 2012-06-21 2014-12-19 Analisis mutacional de adn de plasma para la deteccion de cancer. MX2018013085A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261662878P 2012-06-21 2012-06-21
US201261682725P 2012-08-13 2012-08-13
US201261695795P 2012-08-31 2012-08-31
US201261711172P 2012-10-08 2012-10-08
US13/801,748 US11261494B2 (en) 2012-06-21 2013-03-13 Method of measuring a fractional concentration of tumor DNA

Publications (1)

Publication Number Publication Date
MX2018013085A true MX2018013085A (es) 2021-11-16

Family

ID=52274459

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2014016058A MX360264B (es) 2012-06-21 2013-06-14 Analisis mutacional de adn de plasma para la deteccion de cancer.
MX2018013085A MX2018013085A (es) 2012-06-21 2014-12-19 Analisis mutacional de adn de plasma para la deteccion de cancer.
MX2023001154A MX2023001154A (es) 2012-06-21 2014-12-19 Analisis mutacional de adn de plasma para la deteccion de cancer.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2014016058A MX360264B (es) 2012-06-21 2013-06-14 Analisis mutacional de adn de plasma para la deteccion de cancer.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023001154A MX2023001154A (es) 2012-06-21 2014-12-19 Analisis mutacional de adn de plasma para la deteccion de cancer.

Country Status (19)

Country Link
US (3) US11261494B2 (es)
EP (3) EP3456843B1 (es)
JP (4) JP6371280B2 (es)
KR (6) KR102656030B1 (es)
CN (3) CN107779506B (es)
AU (4) AU2013278994C1 (es)
CA (2) CA3080937A1 (es)
DK (2) DK2864501T3 (es)
EA (2) EA037292B1 (es)
ES (2) ES2894479T3 (es)
HK (3) HK1204013A1 (es)
HU (1) HUE056915T2 (es)
IL (5) IL311127A (es)
MX (3) MX360264B (es)
PT (1) PT3456843T (es)
SG (2) SG11201408113QA (es)
TW (4) TW202328458A (es)
WO (1) WO2013190441A2 (es)
ZA (1) ZA201409281B (es)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3216874A1 (en) 2008-09-05 2017-09-13 TOMA Biosciences, Inc. Methods for stratifying and annotating cancer drug treatment options
US11939634B2 (en) 2010-05-18 2024-03-26 Natera, Inc. Methods for simultaneous amplification of target loci
US11408031B2 (en) 2010-05-18 2022-08-09 Natera, Inc. Methods for non-invasive prenatal paternity testing
US10179937B2 (en) * 2014-04-21 2019-01-15 Natera, Inc. Detecting mutations and ploidy in chromosomal segments
EP3572528A1 (en) 2010-09-24 2019-11-27 The Board of Trustees of the Leland Stanford Junior University Direct capture, amplification and sequencing of target dna using immobilized primers
KR20140024270A (ko) 2010-12-30 2014-02-28 파운데이션 메디신 인코포레이티드 종양 샘플의 다유전자 분석의 최적화
US9892230B2 (en) 2012-03-08 2018-02-13 The Chinese University Of Hong Kong Size-based analysis of fetal or tumor DNA fraction in plasma
US11261494B2 (en) 2012-06-21 2022-03-01 The Chinese University Of Hong Kong Method of measuring a fractional concentration of tumor DNA
US20150011396A1 (en) 2012-07-09 2015-01-08 Benjamin G. Schroeder Methods for creating directional bisulfite-converted nucleic acid libraries for next generation sequencing
US20160040229A1 (en) 2013-08-16 2016-02-11 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
DE202013012824U1 (de) 2012-09-04 2020-03-10 Guardant Health, Inc. Systeme zum Erfassen von seltenen Mutationen und einer Kopienzahlvariation
US10876152B2 (en) 2012-09-04 2020-12-29 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
US11913065B2 (en) 2012-09-04 2024-02-27 Guardent Health, Inc. Systems and methods to detect rare mutations and copy number variation
WO2014144092A1 (en) 2013-03-15 2014-09-18 Nugen Technologies, Inc. Sequential sequencing
EP2971152B1 (en) 2013-03-15 2018-08-01 The Board Of Trustees Of The Leland Stanford Junior University Identification and use of circulating nucleic acid tumor markers
JP6525473B2 (ja) 2013-11-13 2019-06-05 ニューゲン テクノロジーズ， インコーポレイテッド 複製物配列決定リードを同定するための組成物および方法
ES2822125T3 (es) 2013-12-28 2021-04-29 Guardant Health Inc Métodos y sistemas para detectar variantes genéticas
TWI727156B (zh) 2014-07-18 2021-05-11 香港中文大學 Ｄｎａ混合物中之組織甲基化模式分析
KR102441391B1 (ko) * 2014-07-25 2022-09-07 유니버시티 오브 워싱톤 무세포 dna를 생성하는 조직 및/또는 세포 유형을 결정하는 방법 및 이를 사용하여 질환 또는 장애를 확인하는 방법
CA2957633A1 (en) * 2014-08-06 2016-02-11 Nugen Technologies, Inc. Digital measurements from targeted sequencing
PL3198026T3 (pl) * 2014-08-07 2020-05-18 Pharmassist Ltd Metody określania mutacji genu pik3ca w próbce
US11085084B2 (en) 2014-09-12 2021-08-10 The Board Of Trustees Of The Leland Stanford Junior University Identification and use of circulating nucleic acids
US11959141B2 (en) 2014-12-05 2024-04-16 Foundation Medicine, Inc. Multigene analysis of tumor samples
DK3230469T3 (da) 2014-12-12 2019-07-15 Verinata Health Inc Anvendelse af cellefri DNA-fragmentstørrelse til bestemmelse af kopiantalsvariationer
JP6783768B2 (ja) * 2014-12-31 2020-11-11 ガーダント ヘルス， インコーポレイテッド 疾患細胞不均一性を示す疾患の検出および処置、ならびに通信試験結果のためのシステムおよび方法
US10364467B2 (en) * 2015-01-13 2019-07-30 The Chinese University Of Hong Kong Using size and number aberrations in plasma DNA for detecting cancer
CN107771221B (zh) 2015-02-10 2021-11-02 香港中文大学 用于癌症筛查和胎儿分析的突变检测
JP6995625B2 (ja) * 2015-05-01 2022-01-14 ガーダント ヘルス， インコーポレイテッド 診断方法
WO2016183106A1 (en) 2015-05-11 2016-11-17 Natera, Inc. Methods and compositions for determining ploidy
CN104894268B (zh) * 2015-06-05 2018-02-09 上海美吉生物医药科技有限公司 定量样本中源自细胞凋亡的dna浓度的方法及其应用
JP6202659B2 (ja) * 2015-07-01 2017-09-27 学校法人慶應義塾 癌組織の不均一性マーカー及びその使用
JP2017016665A (ja) * 2015-07-03 2017-01-19 国立大学法人東北大学 配列のデータからの変異情報の選択方法、システム、及び、コンピュータプログラム
TWI732771B (zh) 2015-07-20 2021-07-11 香港中文大學 Ｄｎａ混合物中組織之單倍型甲基化模式分析
EP3325664B1 (en) 2015-07-23 2021-12-29 The Chinese University Of Hong Kong Analysis of fragmentation patterns of cell-free dna
US11319586B2 (en) * 2015-08-12 2022-05-03 The Chinese University Of Hong Kong Single-molecule sequencing of plasma DNA
KR20190028821A (ko) 2015-08-25 2019-03-19 난토믹스, 엘엘씨 전이의 유전적 분석을 위한 시스템 및 방법
CN117174167A (zh) 2015-12-17 2023-12-05 夸登特健康公司 通过分析无细胞dna确定肿瘤基因拷贝数的方法
WO2017136603A1 (en) * 2016-02-02 2017-08-10 Guardant Health, Inc. Cancer evolution detection and diagnostic
US10095831B2 (en) 2016-02-03 2018-10-09 Verinata Health, Inc. Using cell-free DNA fragment size to determine copy number variations
KR101810528B1 (ko) * 2016-03-29 2017-12-21 한국과학기술원 단백질을 변화시키지 않는 암 돌연변이의 기능적 recurrence를 구하는 방법 및 장치
US20190085406A1 (en) * 2016-04-14 2019-03-21 Guardant Health, Inc. Methods for early detection of cancer
GB2555765A (en) * 2016-05-01 2018-05-16 Genome Res Ltd Method of detecting a mutational signature in a sample
CN105969856B (zh) * 2016-05-13 2019-11-12 万康源(天津)基因科技有限公司 一种单细胞外显子测序肿瘤体细胞突变检测方法
CN105969656B (zh) * 2016-05-13 2019-09-10 万康源(天津)基因科技有限公司 一种单细胞外显子测序肿瘤体细胞突变检测及分析平台
CN106355045B (zh) * 2016-08-30 2019-03-15 天津诺禾致源生物信息科技有限公司 一种基于扩增子二代测序小片段插入缺失检测的方法及装置
AU2017336153B2 (en) * 2016-09-30 2023-07-13 Guardant Health, Inc. Methods for multi-resolution analysis of cell-free nucleic acids
TWI797095B (zh) 2016-10-24 2023-04-01 美商格瑞爾有限責任公司 腫瘤檢測之方法及系統
GB201618485D0 (en) * 2016-11-02 2016-12-14 Ucl Business Plc Method of detecting tumour recurrence
WO2018090298A2 (en) * 2016-11-17 2018-05-24 Genomicare Biotechnology (Shanghai) Co. Ltd. Systems and methods for monitoring lifelong tumor evolution
KR102529113B1 (ko) 2016-11-30 2023-05-08 더 차이니즈 유니버시티 오브 홍콩 소변 및 기타 샘플에서의 무세포 dna의 분석
CN110383385B (zh) * 2016-12-08 2023-07-25 生命科技股份有限公司 从肿瘤样品中检测突变负荷的方法
CN106845153A (zh) * 2016-12-29 2017-06-13 安诺优达基因科技(北京)有限公司 一种用于利用循环肿瘤dna样本检测体细胞突变的装置
CN106874710A (zh) * 2016-12-29 2017-06-20 安诺优达基因科技(北京)有限公司 一种用于利用肿瘤ffpe样本检测体细胞突变的装置
MY197535A (en) 2017-01-25 2023-06-21 Univ Hong Kong Chinese Diagnostic applications using nucleic acid fragments
US11342047B2 (en) * 2017-04-21 2022-05-24 Illumina, Inc. Using cell-free DNA fragment size to detect tumor-associated variant
JP7123975B2 (ja) * 2017-05-16 2022-08-23 ガーダント ヘルス， インコーポレイテッド 無細胞ｄｎａについての体細胞起源または生殖系列起源の識別
KR102145417B1 (ko) * 2017-05-24 2020-08-19 지니너스 주식회사 무세포 핵산으로부터 수득된 서열 분석 데이터에 대한 배경 대립인자의 빈도 분포를 생성하는 방법 및 이를 이용하여 무세포 핵산으로부터 변이를 검출하는 방법
ES2959360T3 (es) 2017-07-26 2024-02-23 Univ Hong Kong Chinese Mejora del cribado del cáncer mediante ácidos nucleicos víricos acelulares
US20210125683A1 (en) * 2017-09-15 2021-04-29 The Regents Of The University Of California Detecting somatic single nucleotide variants from cell-free nucleic acid with application to minimal residual disease monitoring
CA3075932A1 (en) * 2017-09-20 2019-03-28 Guardant Health, Inc. Methods and systems for differentiating somatic and germline variants
TW201923092A (zh) * 2017-10-10 2019-06-16 美商南托米克斯公司 提高在癌症患者中準確度的綜合基因組轉錄組的腫瘤-正常基因群組分析
US11099202B2 (en) 2017-10-20 2021-08-24 Tecan Genomics, Inc. Reagent delivery system
WO2019090156A1 (en) 2017-11-03 2019-05-09 Guardant Health, Inc. Normalizing tumor mutation burden
JP7013490B2 (ja) * 2017-11-30 2022-02-15 イルミナ インコーポレイテッド 配列バリアントコールのためのバリデーションの方法及びシステム
US20190249229A1 (en) * 2018-02-12 2019-08-15 Nant Holdings Ip, Llc Bam signatures from liquid and solid tumors and uses therefor
WO2019204360A1 (en) * 2018-04-16 2019-10-24 Grail, Inc. Systems and methods for determining tumor fraction in cell-free nucleic acid
CN112888459B (zh) 2018-06-01 2023-05-23 格里尔公司 卷积神经网络系统及数据分类方法
EP3802878A1 (en) * 2018-06-04 2021-04-14 Guardant Health, Inc. Methods and systems for determining the cellular origin of cell-free nucleic acids
EP3827100A2 (en) * 2018-07-23 2021-06-02 Guardant Health, Inc. Methods and systems for adjusting tumor mutational burden by tumor fraction and coverage
CN112424380A (zh) * 2018-11-01 2021-02-26 Illumina公司 用于体细胞变体检测的方法和组合物
US11581062B2 (en) 2018-12-10 2023-02-14 Grail, Llc Systems and methods for classifying patients with respect to multiple cancer classes
CN117778576A (zh) 2018-12-19 2024-03-29 香港中文大学 游离dna末端特征
US20200219587A1 (en) * 2018-12-21 2020-07-09 Grail, Inc. Systems and methods for using fragment lengths as a predictor of cancer
CN109616198A (zh) * 2018-12-28 2019-04-12 陈洪亮 仅用于肝癌单一癌种筛查的特异甲基化检测位点组合的选取方法
CN109686414A (zh) * 2018-12-28 2019-04-26 陈洪亮 仅用于肝癌筛查的特异甲基化检测位点组合的选取方法
CN109817279B (zh) * 2019-01-18 2022-11-04 臻悦生物科技江苏有限公司 肿瘤突变负荷的检测方法、装置、存储介质及处理器
KR102381252B1 (ko) * 2019-02-19 2022-04-01 주식회사 녹십자지놈 혈중 무세포 dna 기반 간암 치료 예후예측 방법
CN109841265B (zh) * 2019-02-22 2021-09-21 清华大学 使用片段化模式确定血浆游离核酸分子组织来源的方法和系统及应用
CN109920480B (zh) * 2019-03-14 2020-02-21 深圳市海普洛斯生物科技有限公司 一种校正高通量测序数据的方法和装置
CN111755075B (zh) * 2019-03-28 2023-09-29 深圳华大生命科学研究院 对免疫组库高通量测序样本间序列污染进行过滤的方法
CA3139535A1 (en) * 2019-05-17 2020-11-26 Ultima Genomics, Inc. Methods and systems for detecting residual disease
CN111223525A (zh) * 2020-01-07 2020-06-02 广州基迪奥生物科技有限公司 一种肿瘤外显子测序数据分析方法
US11211147B2 (en) 2020-02-18 2021-12-28 Tempus Labs, Inc. Estimation of circulating tumor fraction using off-target reads of targeted-panel sequencing
US11475981B2 (en) 2020-02-18 2022-10-18 Tempus Labs, Inc. Methods and systems for dynamic variant thresholding in a liquid biopsy assay
US11211144B2 (en) 2020-02-18 2021-12-28 Tempus Labs, Inc. Methods and systems for refining copy number variation in a liquid biopsy assay
AU2022300887A1 (en) * 2021-06-30 2024-01-25 Memorial Hospital For Cancer And Allied Diseases Detection of somatic mutational signatures from whole genome sequencing of cell-free dna
KR20230085239A (ko) * 2021-12-06 2023-06-14 주식회사 지씨지놈 혈중 무세포 dna 기반 유방암 치료 예후예측 방법
CN115064212B (zh) * 2022-06-24 2023-03-14 哈尔滨星云生物信息技术开发有限公司 基于wgs数据的预设区域人群肿瘤特异突变识别方法
WO2024003936A1 (en) 2022-06-29 2024-01-04 Raman Govindarajan Method for detecting cancer susceptibility, early detection and predicting cancer behaviour
CN117012274B (zh) * 2023-10-07 2024-01-16 北京智因东方转化医学研究中心有限公司 基于高通量测序识别基因缺失的装置

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU72901A (sh) 1999-04-02 2004-07-15 Corixa Corporation Preparati za primenu u terapiji i dijagnozi raka pluća
US20030219765A1 (en) 2000-03-23 2003-11-27 Jose Costa Methods for evaluating cancer risk
EP1468104A4 (en) 2002-01-18 2006-02-01 Genzyme Corp METHODS FOR DETECTION OF FETAL DNA AND QUANTIFICATION OF ALLELES
EP2292787B1 (en) 2002-05-10 2017-03-22 City of Hope Pyrophosphorolysis activated polymerization (PAP)
US7704687B2 (en) 2002-11-15 2010-04-27 The Johns Hopkins University Digital karyotyping
US20060188889A1 (en) * 2003-11-04 2006-08-24 Christopher Burgess Use of differentially expressed nucleic acid sequences as biomarkers for cancer
AU2004217872B2 (en) 2003-03-05 2010-03-25 Genetic Technologies Limited Identification of fetal DNA and fetal cell markers in maternal plasma or serum
PL201608B1 (pl) 2003-06-13 2009-04-30 Cezary Cybulski Sposób i zestaw do wykrywania wysokiej genetycznie uwarunkowanej predyspozycji do raka prostaty oraz zastosowanie zmiany germinalnej w obrębie genu NBS1
EP1524321B2 (en) 2003-10-16 2014-07-23 Sequenom, Inc. Non-invasive detection of fetal genetic traits
WO2005108621A1 (en) 2004-04-30 2005-11-17 Yale University Methods and compositions for cancer diagnosis
JP5219516B2 (ja) * 2005-03-18 2013-06-26 ザ チャイニーズ ユニバーシティー オブ ホンコン 染色体異数性の検出方法
US20070122823A1 (en) 2005-09-01 2007-05-31 Bianchi Diana W Amniotic fluid cell-free fetal DNA fragment size pattern for prenatal diagnosis
US7888017B2 (en) 2006-02-02 2011-02-15 The Board Of Trustees Of The Leland Stanford Junior University Non-invasive fetal genetic screening by digital analysis
ATE508209T1 (de) 2006-02-28 2011-05-15 Univ Louisville Res Found Erkennung von chromosomabnormalitäten im fötus mit hilfe der tandem-einzelnukleotid- polymorphismen
WO2008024009A1 (fr) 2006-08-15 2008-02-28 Institut Molekulyarnoi Genetiki Rossiiskoi Akademii Nauk (Img Ran) Niveau de transcription du gène timp3 utilisé en tant que marqueur servant à diagnostiquer le cancer du poumon non à petites cellules
JP2010527603A (ja) 2007-05-25 2010-08-19 ディコーデ ジェネテクス イーエイチエフ 乳癌のリスクアセスメント、診断、予後診断および治療における使用のためのマーカーとしてのＣＨＲ５ｐ１２および１０ｑ２６上の遺伝的変異
KR20230117256A (ko) 2007-07-23 2023-08-07 더 차이니즈 유니버시티 오브 홍콩 대규모 병렬 게놈 서열분석을 이용한 태아 염색체 이수성의진단 방법
US20090053719A1 (en) 2007-08-03 2009-02-26 The Chinese University Of Hong Kong Analysis of nucleic acids by digital pcr
US20100041048A1 (en) 2008-07-31 2010-02-18 The Johns Hopkins University Circulating Mutant DNA to Assess Tumor Dynamics
EP2952589B1 (en) * 2008-09-20 2018-02-14 The Board of Trustees of The Leland Stanford Junior University Noninvasive diagnosis of fetal aneuploidy by sequencing
US20100136560A1 (en) 2008-12-02 2010-06-03 The Johns Hopkins University Integrated Analyses of Breast and Colorectal Cancers
SG174401A1 (en) 2009-03-31 2011-11-28 Oridis Biomarkers Gmbh Method for diagnosis of cancer and monitoring of cancer treatments
US20120208711A1 (en) 2009-10-02 2012-08-16 Centre For Addiction And Mental Health Method for Analysis of DNA Methylation Profiles of Cell-Free Circulating DNA in Bodily Fluids
WO2011053790A2 (en) 2009-10-30 2011-05-05 Fluidigm Corporation Assay of closely linked targets in fetal diagnosis and coincidence detection assay for genetic analysis
DK2496717T3 (en) 2009-11-05 2017-07-24 Univ Hong Kong Chinese ANALYSIS OF BORN THROUGH FROM A MATERNAL BIOLOGICAL TEST
EP2496713B1 (en) 2009-11-06 2018-07-18 The Chinese University of Hong Kong Size-based genomic analysis
GB0922006D0 (en) 2009-12-17 2010-02-03 Genome Res Ltd Diagnostic
WO2011091046A1 (en) 2010-01-19 2011-07-28 Verinata Health, Inc. Identification of polymorphic sequences in mixtures of genomic dna by whole genome sequencing
AU2010343276B2 (en) 2010-01-19 2015-05-28 Verinata Health, Inc. Methods for determining fraction of fetal nucleic acid in maternal samples
EP2536854B1 (en) 2010-02-18 2017-07-19 The Johns Hopkins University Personalized tumor biomarkers
EP2426217A1 (en) 2010-09-03 2012-03-07 Centre National de la Recherche Scientifique (CNRS) Analytical methods for cell free nucleic acids and applications
WO2012071621A1 (en) 2010-11-30 2012-06-07 The Chinese University Of Hong Kong Detection of genetic or molecular aberrations associated with cancer
JP6161607B2 (ja) 2011-07-26 2017-07-12 ベリナタ ヘルス インコーポレイテッド サンプルにおける異なる異数性の有無を決定する方法
DK2764459T3 (da) 2011-10-06 2021-08-23 Sequenom Inc Fremgangsmåder og processer til ikke-invasiv bedømmelse af genetiske variationer
WO2013086352A1 (en) 2011-12-07 2013-06-13 Chronix Biomedical Prostate cancer associated circulating nucleic acid biomarkers
US9892230B2 (en) 2012-03-08 2018-02-13 The Chinese University Of Hong Kong Size-based analysis of fetal or tumor DNA fraction in plasma
CA2867293C (en) 2012-03-13 2020-09-01 Abhijit Ajit PATEL Measurement of nucleic acid variants using highly-multiplexed error-suppressed deep sequencing
US11261494B2 (en) 2012-06-21 2022-03-01 The Chinese University Of Hong Kong Method of measuring a fractional concentration of tumor DNA
DE202013012824U1 (de) 2012-09-04 2020-03-10 Guardant Health, Inc. Systeme zum Erfassen von seltenen Mutationen und einer Kopienzahlvariation
SG11201506660RA (en) 2013-02-21 2015-09-29 Toma Biosciences Inc Methods, compositions, and kits for nucleic acid analysis
WO2014145078A1 (en) 2013-03-15 2014-09-18 Verinata Health, Inc. Generating cell-free dna libraries directly from blood
US10174375B2 (en) 2013-09-20 2019-01-08 The Chinese University Of Hong Kong Sequencing analysis of circulating DNA to detect and monitor autoimmune diseases
US10262755B2 (en) 2014-04-21 2019-04-16 Natera, Inc. Detecting cancer mutations and aneuploidy in chromosomal segments
KR102441391B1 (ko) 2014-07-25 2022-09-07 유니버시티 오브 워싱톤 무세포 dna를 생성하는 조직 및/또는 세포 유형을 결정하는 방법 및 이를 사용하여 질환 또는 장애를 확인하는 방법

Also Published As

Publication number Publication date
IL278867B1 (en) 2023-01-01
US20190264291A1 (en) 2019-08-29
KR102656030B1 (ko) 2024-04-08
AU2017204558B2 (en) 2019-10-10
TW202122796A (zh) 2021-06-16
KR20220038181A (ko) 2022-03-25
KR20200035507A (ko) 2020-04-03
SG11201408113QA (en) 2015-01-29
MX2014016058A (es) 2015-04-10
IL235967B (en) 2019-09-26
DK2864501T3 (en) 2018-11-05
CN107779506B (zh) 2022-07-15
KR102237923B1 (ko) 2021-04-08
KR20180088922A (ko) 2018-08-07
CA2876327C (en) 2020-09-29
TW202328458A (zh) 2023-07-16
MX360264B (es) 2018-10-26
JP2024026360A (ja) 2024-02-28
AU2020200122A1 (en) 2020-01-30
EP3919627A1 (en) 2021-12-08
HK1205533A1 (en) 2015-12-18
CN107779506A (zh) 2018-03-09
IL278867B2 (en) 2023-05-01
JP2018191640A (ja) 2018-12-06
IL268645A (en) 2019-10-31
PT3456843T (pt) 2021-10-26
EP2864501A4 (en) 2016-03-16
AU2022209294A1 (en) 2022-08-25
IL311127A (en) 2024-04-01
EP2864501B1 (en) 2018-08-08
EP3456843B1 (en) 2021-07-28
AU2013278994C1 (en) 2019-12-12
KR102096611B1 (ko) 2020-04-02
US20180202003A1 (en) 2018-07-19
KR102521842B1 (ko) 2023-04-14
EP3456843A1 (en) 2019-03-20
TW201920952A (zh) 2019-06-01
EA202092900A3 (ru) 2021-06-30
CA2876327A1 (en) 2013-12-27
KR20210040464A (ko) 2021-04-13
CN104662168A (zh) 2015-05-27
KR102375645B1 (ko) 2022-03-17
US11261494B2 (en) 2022-03-01
SG10201808217WA (en) 2018-10-30
EP2864501A2 (en) 2015-04-29
ES2687847T3 (es) 2018-10-29
US20140100121A1 (en) 2014-04-10
EA201500027A1 (ru) 2015-05-29
CA3080937A1 (en) 2013-12-27
TWI803505B (zh) 2023-06-01
ES2894479T3 (es) 2022-02-14
JP2015527057A (ja) 2015-09-17
KR101884909B1 (ko) 2018-08-02
TWI786428B (zh) 2022-12-11
AU2013278994A1 (en) 2015-01-29
WO2013190441A2 (en) 2013-12-27
KR20230052998A (ko) 2023-04-20
JP7408161B2 (ja) 2024-01-05
ZA201409281B (en) 2017-08-30
TW201403066A (zh) 2014-01-16
CN104662168B (zh) 2017-12-05
EA202092900A2 (ru) 2021-03-31
HK1246830A1 (zh) 2018-09-14
IL298810B1 (en) 2024-04-01
AU2017204558A1 (en) 2017-07-27
HUE056915T2 (hu) 2022-03-28
AU2013278994B2 (en) 2017-04-06
IL235967A0 (en) 2015-01-29
CN113151474A (zh) 2021-07-23
JP6371280B2 (ja) 2018-08-08
AU2020200122B2 (en) 2022-05-19
IL298810A (en) 2023-02-01
EA037292B1 (ru) 2021-03-05
KR20150032708A (ko) 2015-03-27
MX2023001154A (es) 2023-02-22
WO2013190441A3 (en) 2014-02-27
IL278867A (en) 2021-01-31
JP2021191280A (ja) 2021-12-16
JP6930948B2 (ja) 2021-09-01
TWI636255B (zh) 2018-09-21
HK1204013A1 (en) 2015-11-06
DK3456843T3 (da) 2021-10-25

Similar Documents

Publication Publication Date Title
MX2018013085A (es) Analisis mutacional de adn de plasma para la deteccion de cancer.
Siqueira et al. LDA vs. QDA for FT-MIR prostate cancer tissue classification
Pomerantsev et al. On the type II error in SIMCA method
EP2371447A3 (en) High-pressure vessel for microwave synthesis
CN104134252A (zh) 进出室管理装置
da Cunha Santos Standardizing preanalytical variables for molecular cytopathology
López Intratumor heterogeneity in clear cell renal cell carcinoma: a review for the practicing pathologist
Stone Radio frequency based programmable logic controller anomaly detection
Laleh et al. Benchmarking artificial intelligence methods for end-to-end computational pathology
Baiocchi et al. Recurrence in node-negative advanced gastric cancer: Novel findings from an in-depth pathological analysis of prognostic factors from a multicentric series
Kikutake et al. Pan-cancer analysis of intratumor heterogeneity associated with patient prognosis using multidimensional measures
Dickson et al. Real‐world data in the molecular era—finding the reality in the real world
William et al. Unravelling the application of machine learning in cancer biomarker discovery
Rezaei-Tavirani et al. Breast cancer interaction network concept from mostly related components
Bocci et al. A biophysical model of Epithelial-Mesenchymal Transition uncovers the frequency and size distribution of Circulating Tumor Cell clusters across cancer types
Macrae et al. Acceleration in colorectal carcinogenesis: the hare, the tortoise or myth?
CN205162437U (zh) 一种电脑柜
Shafi A Systems Biology Approach To Identify Dna Methylation Based Disease Biomarkers
Innocenti et al. Translating the cancer genome into clinically useful tools and strategies
CN104732130A (zh) 移动终端控制电子设备进行操作的方法及该移动终端
Yang Integrated analysis of DNA methylation profiles in the malignant brain tumor glioblastom
McGee et al. Molecular tumor classification using a 92-gene assay in the differential diagnosis of squamous cell lung cancer
Fitzgerald A Survey of Wavelet Theory and Methods Suited for Times Series Analysis
Wan Mahamad Modelling of Electromagnetic Wave Using Statistical/Numerical Approach
CN109889287A (zh) 一种基于四元假设检验的非法信号源检测方法